OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
Wolf M, Rubin J, Achebe M, Econs M, Peacock M, Imel E, Thomsen L, Carpenter T, Weber T, Zoller H. OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials. Journal Of The Endocrine Society 2019, 3: or13-3. PMCID: PMC6554827, DOI: 10.1210/js.2019-or13-3.Peer-Reviewed Original ResearchIron deficiency anemiaPg/mLFerric carboxymaltoseIron isomaltosideVitamin DIntact FGF23Day 1Day 35Bone turnoverPhosphate excretionIIM groupCorrection of IDADay 8Urinary fractional phosphate excretionBone-specific alkaline phosphataseFractional phosphate excretionNew intravenous iron preparationsIncidence of hypophosphatemiaSevere hypersensitivity reactionsGrowth factor 23Intravenous iron preparationsRenal phosphate excretionRandomized Controlled TrialsRenal phosphate wastingSpecific alkaline phosphatase
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply